Participants
esophageal varicose veins or portal shunt, alcohol addiction, allergy, CDI, liver disease, liver cirrhosis, PD, infection, Parkinson’s disease, renal disease, enterobacteria, mental disorders, arrhythmias, renal damage, tumors
CYTOMEGALOVIRUS, ACUTE INFECTIONS, NEPHROTIC SYNDROME, ALLERGY, LIVER DISEASE, LIVER CIRRHOSIS, INFECTION, DISEASES OF THE HEART, PLAGUE, HEPATIC ENCEPHALOPATHY, RENAL DISEASE, SALMONELLA, SHIGELLA, ARRHYTHMIAS, TUMORS
Subjects aged 30 to 85 who were diagnosed with mild to moderate PD (Hoehn-Yahr stage 1 to 3) according to the diagnostic criteria for PD in China (2016 edition) were enrolled. Detailed inclusion criteria are as follows: 1) male and female aged 30 to 85 years, 2) patients with early Parkinson’s disease are diagnosed as having H-Y 1 ~ 3 grade of Parkinson’s disease in accordance with the diagnostic criteria for Parkinson’s disease in China (2016 edition), 3) with no specific difficulty in communication, 4) sign the informed consent and agree to participate in this study. Detailed exclusion criteria are as follows: 1) complicated with other serious diseases of the heart, liver, kidney, respiratory, digestive, blood and endocrine systems, 2) combined with intestinal double infection, such as CDI, ehec, salmonella, shigella, campylobacter, plague, and cytomegalovirus, 3) liver function was significantly abnormal or had the following liver disease history: AST or ALT was twice higher than the upper limit of normal value (AST: 59 U/L, ALT: 50 U/L), history of liver cirrhosis, hepatic encephalopathy, history of esophageal varicose veins or portal shunt, 4) with evidence of renal damage or the following renal disease history: serum creatinine is 1.5 times higher than the upper limit of normal value; The history of dialysis; Or a history of nephrotic syndrome, 5) patients with various acute infections, tumors and severe arrhythmias, mental disorders, drug or alcohol addiction, 6) pregnant or lactating women, 7) have used antibiotics or microecological agents in the past 4 weeks, 8) patients with allergy or contraindications to “enterobacteria capsule” used in this study, 9) clinical researchers with other related Parkinson’s disease were being conducted at the time of enrollment or within 3 months before enrollment, 10) it is difficult to complete the interview, or various factors affecting the compliance.According to current reports, the therapeutic efficacy of PD patients is about 48%, and the estimated efficacy of FMT on PD patients is 80%. Assuming the allocation of 1:1, type 1 error of 0.05 (α), and power of 0.9 (1-β), based on former reports about conventional treatment and FMT on Parkinson’s disease, 56 participants were enrolled assuming a 10% dropout rate to detect a minimum difference in MDS-UPDRS scores between the FMT and placebo groups.